Overview

A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to test for bioequivalence of VIAject®7 and VIAject®25 and to compare the pharmacokinetic/Pharmacodynamic/tolerability characteristics of VIAject®7 with those of VIAject®25 and insulin lispro.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Biodel

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc